Inhibitory effects of leflunomide therapy on the activity of matrixmetalloproteinase-9 and the release of cartilage oligomeric matrix protein in patients with rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 24, Issue 2, 2006, Pages 155-160

  Kullich, Werner C ^a   Mur, Erich ^b   Aglas, Ferdinand ^c   Niksic, Franz ^a   Czerwenka, Christoph ^d  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b Clinic of Internal Medicine   (Austria)

^c Clinic St Barbara   (Austria)

^d EMCO Private Clinic   (Austria)

Author keywords

Cartilage oligomeric matrix protein; Leflunomide; Metalloproteinase; Rheumatoid arthritis; Serum amyloid A

Indexed keywords

AMYLOID A PROTEIN; CARTILAGE OLIGOMERIC MATRIX PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GELATINASE B; INTERSTITIAL COLLAGENASE; LEFLUNOMIDE; NONSTEROID ANTIINFLAMMATORY AGENT;

ALOPECIA; ARTICLE; BLOOD SAMPLING; CHONDROPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFECT; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; ENZYME INHIBITION; FEMALE; HUMAN; IMMUNOMODULATION; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; RASH; RHEUMATOID ARTHRITIS; STOMATITIS; TREATMENT OUTCOME; VERTIGO;

ADJUVANTS, IMMUNOLOGIC; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CARTILAGE, ARTICULAR; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GLYCOPROTEINS; HUMANS; ISOXAZOLES; MALE; MATRIX METALLOPROTEINASE 9; SERUM AMYLOID A PROTEIN; TREATMENT OUTCOME;

EID: 33744806349     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. HAZES JM, WOOLF AD: The bane and joint decade 2000-2010. J Rheumatol 2000; 27: 1-3.
2. FOX RI: Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol 1998; 25 (Suppl. 53): 20-6.
3. SHARP JT, STRAND V, LEUNG H, HURLEY F, LOEW-FRIEDRICH I: Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 2000; 43: 495-505.
4. SMOLEN JS, KALDEN JR, SCOTT DL et al.: Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999; 353: 259-66.
5. COHEN S, CANNON GW, SCHIFF M et al.: Two-Year, Blinded, Randomized, Controlled Trial of Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Methotrexate. Arthritis Rheum 2001; 44: 1984-92.
6. SCOTT DL, SMOLEN JS, KALDEN JR et al.: Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus Sulfasalazin. Ann Rheun Dis 2001; 60: 913-23.
7. PANICO A, CARDILE V, GENTILE B et al.: Effects of leflunomide on human cartilage. Farmaco 2003; 58: 983-87.
8. MAUVIEL A: Cytokine regulation of metalloproteinase gene expression. J Cell Biochem 1993; 53: 288-95.
9. BRENNAN FM, BROWNE KA, GREEN PA, JASPAR JM, MAINI RN, FELDMANN M: Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor alpha (cA2) therapy. Br J Rheumatol 1997; 36: 643-50.
10. JOVANOVIC DV, MARTEL-PELLETIER J, DI BATTISTA JA et al.: Stimulation of 92-kd gelatinase (matrix metalloproteinase 9) production by interleukin-17 in human monocyte/macrophages. Arthritis Rheum 2000; 43: 1134-44.
11. MÜLLER-LADNER U: Rheumatoide Arthritis. In: GANTEN D, RUCKPAUL K (Eds.): Molekularmedizinische Grundlagen von rheumatischen Erkrankungen. Springer Verlag Berlin-Heidelberg, 2003: 255-289.
12. AHRENS D, KOCH AE, POPE RM, STEINPICARELLA M, NIEDBALA MJ: Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum 1996; 39: 1576-87.
13. MIGITA K, MIYASHITA T, ISHIBASHI H et al.: Suppressive effect of leflunomide metabolite (A77 1726) on metalloproteinase production in IL-1beta stimulated rheumatoid synovial fibroblasts. Clin Exp Immunol 2004; 137: 612-16.
14. LARSSON E, MÜSSENER A, HEINEGARD D, KLARESKOG L, SAXNE T: Increased serum levels of cartilage oligomeric matrix protein and bone sialoprotein in rats with collagen arthritis. Br J Rheumatol 1997; 36: 1258-61.
15. DI CESARE PE, CARLSON CS, STOLLERMAN ES, CHEN FS, LESLIE M, PERRIS R: Expression of cartilage oligomeric matrix protein by human synovium. FEBS Letters 1997; 412: 249-52.
16. MORGELIN M, HEINEGARD D, ENGEL J, PAULSON M: Electron microscopy of native cartilage oligomeric matrix protein purified from the Swarm rat chondrosarcoma reveals a five-armed structure. J Biol Chem 1992; 267: 6137-41.
17. OLDBERG A, ANTONSSON P, LINDBLOM K, HEINEGARD D: COMP (cartilage oligomeric matrix protein) is structurally related to the thrombospondins. J Biol Chem 1992; 267: 22346-50.
18. FORSLIND K, EBERHARDT K, JONSSON A, SAXNE T: Increased serum concentrations of cartilage oligomeric matrix protein. A prognostic marker in early rheumatoid arthritis. Br J Rheumatol 1992; 31: 593-98.
19. MARTI C, NEIDHART M, GERBER T, HAUSER N, MICHEL BA, HÄUSELMANN HI: Cartilage Oligomeric Matrix Protein (COMP): Die Rolle eines nichtkollagenen Knorpel-Matrix-Proteins als Marker der Krankheitsaktivität und Gelenkzerstörung bei Patienten mit rheumatoider Arthritis und Arthrose. Z Rheumatol 1999; 58: 79-87.
20. RECKLIES AD, BAILLARGEON L, WHITE C: Regulation of cartilage oligomeric matrix protein synthesis in human synovial cells and articular chondrocytes. Arthritis Rheum 1998; 41: 997-1006.
21. KOOLWIJK P, MILTENBERG AMM, VAN ERCK MGM et al.: Activated gelatinase-B (MMP-9) and urokinase-type plasminogen activator in synovial fluids of patients with arthritis: correlation with clinical and experimental variables of inflammation. J Rheumatol 1995; 22: 385-93.
22. TETLOW LC, LEES M, OGATA Y, NAGASE H, WOOLLEY DE: Differential expression of gelatinase B (MMP-9) and stromelysin-1 (MMP-3) by rheumatoid synovial cells in vitro and in vivo. Rheumatol Int 1993; 13: 53-9.
23. GIANNELLI G, ERRIQUEZ R, IANNONE F, MARINOSCI F, LAPADULA G, ANTONACI S: MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in patients with rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumatol 2004; 22: 335-8.
24. VINGSBO-LUNDBERG C, SAXNE T, OLSSON H, HOLMDAHL R: Increased serum levels of cartilage oligomeric matrix protein in chronic erosive arthritis in rats. Arthritis Rheum 1998; 41: 544-50.
25. KULLICH W: Effect on an in-patient rehabilitation on cartilage oligomeric matrix protein in rheumatoid arthritis. Swiss Med Wkly 2003; 133 (Suppl.136): 3.
26. ROUX-LOMBARD P, EBERHARDT K, SAXNE T, DAYER JM, WOLLHEIM FA: Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study. Rheumatology 2001; 40: 544-51.
27. MALLE E, DEBEER FC: Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest 1996; 26: 427-35.
28. YAMADA T, OKUDA Y, TAKASUGI K, ITOH K, IGARI J: Relative serum amyloid A (SAA) values: the influence of SAA1 genotypes and corticosteroid treatment in Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2001; 60: 124-7.
29. MIGITA K, MIYASHITA T, MAEDA Y et al.: An active metabolite of leflunomide, A77 1726, inhibits the production of serum amyloid A protein in human hepatocytes. Rheumatology 2005; 44: 443-8.
30. KRAAN MC, REECE RJ, BARG EC et al.: Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Arthritis Rheum 2000; 43: 1820-30.
31. ELKAYAM O, YARON I, SHIRAZI I, JUDOVITCH R, CASPI D, YARON M: Active leflunomide metabolite inhibits interleukin 1beta, tumour necrosis factor alpha, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue cultures. Ann Rheum Dis 2003; 62: 440-3.